Загрузка...
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of the EGFR, were approved in many countries for the treatm...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3244201/ https://ncbi.nlm.nih.gov/pubmed/22229045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834011427927 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|